Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors by Blum, Kenneth et al.
Int. J. Environ. Res. Public Health 2011, 8, 4425-4459; doi:10.3390/ijerph8124425 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Article 
Generational Association Studies of Dopaminergic Genes in 
Reward Deficiency Syndrome (RDS) Subjects: Selecting 
Appropriate Phenotypes for Reward Dependence Behaviors 
Kenneth Blum 
1,11,14,16,17,18,19,*, Amanda L. C. Chen 
2,*, Marlene Oscar-Berman 
3,  
Thomas J. H. Chen 
4, Joel Lubar 
5, Nancy White 
6, Judith Lubar 
7, Abdalla Bowirrat 
8,  
Eric Braverman 
9,14, John Schoolfield 
10, Roger L. Waite 
11, Bernard W. Downs 
11,
  
Margaret Madigan 
11, David E. Comings 
12, Caroline Davis 
13, Mallory M. Kerner 
14,  
Jennifer Knopf 
14, Tomas Palomo 
15, John J. Giordano 
16,17, Siobhan A. Morse 
16,17,  
Frank Fornari 
18, Debmalya Barh 
19, John Femino 
20 and John A. Bailey 
1 
1  Department of Psychiatry, School of Medicine and McKnight Brain Institute, University of Florida, 
W University Ave., Gainesville, FL 32601, USA; E-Mail: baileyjo@ufl.edu 
2  Department of Engineering Management Advanced Technology, Chang Jung Christian University, 
No. 396, Sec. 1, Changrong Road, Tainan 71101, Taiwan 
3  Department of Anatomy & Neurobiology, Boston University School of Medicine, 72 East Concord 
Street, Boston, MA 02118, USA; E-Mail: Oscar@bu.edu 
4  Department of Occupational Safety and Health, Chang Jung Christian University, No. 396,  
Sec. 1, Changrong Road, Tainan 71101, Taiwan; E-Mail: tjhchen@yahoo.com.tw 
5  Emeritus, Department of Physiology, University of Tennessee, 719 Andy Holt Tower, Knoxville, 
TN 37996, USA; E-Mail: lubar@utkux.utcc.utk.edu 
6  Unique Mindcare, Inc., 1900 Saint James Place, Houston, TX 77056, USA;  
E-Mail: nancy@Uniquemindcare.com  
7  Department of Neurofeedback, Southeastern Biofeedback and Neurobehavioral Clinic,  
101 Westwood Road, Knoxville, TN 37919, USA; E-Mail: lubar@utkux.utcc.utk.edu 
8  Department of Neuroscience & Population Genetics, EMMS Nazareth Hospital, Nazareth, Israel;  
E-Mail: bowirrat@netvision.net.il  
9  Department of Neurosurgery, Weill Cornell College of Medicine, 1300 York Ave., New York,  
NY 10065, USA; E-Mail: pathfoundationny@gmail.com 
10  Department of Academic Informatics Services, University of Texas Health Science Center,  
7703 Floyd Curl Drive, San Antonio, TX 78229, USA; E-Mail: schoolfield@uthscsa.edu 
11  Department of Nutrigenomics, LifeGen, Inc., P.O. Box 366, 570 Lederach Stattion Way, Lederach, PA 
19450, USA; E-Mails: drw8@san.rr.com (R.L.W.); bernardwdowns@gmail.com (B.W.D.); 
MARGBETTS@hotmail.com (M.M.) 
OPEN ACCESS Int. J. Environ. Res. Public Health 2011, 8                 
 
4426 
12  Department of Genomic Research, Carlsbad Science Foundation, Department of Medical Genetics, 
City of Hope National Medical Center, 1500 Duarte Road, Duarte, CA 91010, USA;  
E-Mail: dcomings@earthlink.net 
13  Department of Kinesiology and Health Sciences, York University, 4700 Keele Street, Toronto,  
ON M3J 1P3, Canada; E-Mail: cdavis@yorku.ca 
14  Department of Integrative Medicine, PATH Medical Research Foundation, 304 Park Ave. South, 
New York, NY 10010, USA; E-Mails: Mallory.kerner@gmail.com (M.M.K.); 
info@pathfoundationny.org (J.K.) 
15  Hospital Universitario 12 de Octubre, Servicio de Psiquiatria, Av. Cordoba SN, Madrid 28041, 
Spain; E-Mail: tpalomo2004@yahoo.es
 
16  Department of Holistic Medicine, G&G Holistic Addiction Treatment, Inc., 1590 Northeast  
162nd Street, North Miami Beach, FL 33162, USA; E-Mail: michg8@hotmail.com 
17  Department of Research, National Institute for Holistic Addiction Studies, 1590 Northeast  
162nd Street, North Miami Beach, FL 33162, USA; E-Mail: samorse10@aol.com 
18  Dominion Diagnostics, Inc., 211 Circuit Road, North Kingstown, RI 02852, USA;  
E-Mail: ffornari@me.com 
19  Center for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied 
Biotechnology, Nonakuri, Purba Medinipur, West Bengal, India; E-Mail: dr.barh@gmail.com 
20  Meadows Edge Recovery Center, 580 10 Rod Road, North Kingstown, RI 02852, USA;  
E-Mail: jfemino@meadowsedge.com  
*  Authors to whom correspondence should be addressed; E-Mails: drd2gene@aol.com (K.B.); 
tjhchen@yahoo.com.tw (A.L.C.C.).  
Received: 26 October 2011; in revised form: 23 November 2011 / Accepted: 23 November 2011 / 
Published: 29 November 2011 
 
Abstract: Abnormal behaviors involving dopaminergic gene polymorphisms often reflect 
an insufficiency of usual feelings of satisfaction, or Reward Deficiency Syndrome (RDS). 
RDS results from a dysfunction in the “brain reward cascade,” a complex interaction 
among neurotransmitters (primarily dopaminergic and opioidergic). Individuals with a 
family history of alcoholism or other addictions may  be born with a deficiency in the 
ability to produce or use these neurotransmitters. Exposure to prolonged periods of stress 
and alcohol or other substances also can lead to a corruption of the brain reward cascade 
function. We evaluated the potential association of four variants of dopaminergic candidate 
genes in RDS (dopamine D1 receptor gene [DRD1]; dopamine D2 receptor gene [DRD2]; 
dopamine transporter gene [DAT1]; dopamine beta-hydroxylase gene [DBH]). Methodology: 
We genotyped an experimental group of 55 subjects derived from up to five generations of 
two independent multiple-affected families compared to rigorously screened control 
subjects (e.g., N = 30 super controls for DRD2 gene polymorphisms). Data related to RDS 
behaviors were collected on these  subjects plus 13 deceased family members. Results: 
Among the genotyped family members, the DRD2 Taq1 and the DAT1 10/10 alleles were Int. J. Environ. Res. Public Health 2011, 8                 
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significantly (at least p < 0.015) more often found in the RDS families vs. controls. The 
TaqA1 allele occurred in 100% of Family A individuals (N = 32) and 47.8% of Family B 
subjects (11 of 23). No significant differences were found between the experimental and 
control positive rates for the other variants. Conclusions: Although our sample size was 
limited, and linkage analysis is necessary, the results support the putative role of 
dopaminergic polymorphisms in RDS behaviors. This study shows the importance of a 
nonspecific RDS phenotype and informs an understanding of how evaluating single subset 
behaviors of RDS may lead to  spurious results. Utilization of a nonspecific “reward” 
phenotype may be a paradigm shift in future association and linkage studies involving 
dopaminergic polymorphisms and other neurotransmitter gene candidates. 
Keywords: dopamine; gene polymorphisms; generational association studies; phenotype; 
“super normal” controls; Reward Deficiency Syndrome (RDS)  
 
1. Introduction 
1.1. Background 
Reward Deficiency Syndrome (RDS) was first defined by our lab in 1996 as a putative predictor of 
impulsive and addictive behaviors [1-7]. It refers to an absence of usual feelings of satisfaction and a 
failure of the system that normally confers gratification, resulting in behaviors such as overeating, 
heavy cigarette smoking, drug and alcohol abuse, gambling, and hyperactivity (see Table 1 in a later 
section). The syndrome has been linked to dysfunction of dopamine (DA) receptors, the genes for 
which show many mutant forms. In an attempt to resolve controversy regarding the causal 
contributions of mesolimbic DA systems to reward, we have  evaluated  the three main competing 
explanatory categories: “liking,” “learning,” and “wanting” [8], especially as they relate to RDS [9]. 
That is, DA may mediate:  (a) the hedonic impact of reward (liking), (b) learned predictions   
about rewarding effects (learning), or (c) the pursuit of rewards by attributing incentive salience to  
reward-related stimuli (wanting). We evaluated  these hypotheses, especially as they relate to the 
Reward Deficiency Syndrome (RDS), and we find that the incentive salience or “wanting” hypothesis 
of DA function is supported by a majority of the evidence [9].  
Neuroimaging studies have shown that drugs of abuse, palatable foods, and anticipated behaviors 
such as sex and gaming affect brain regions involving reward circuitry, and may not be unidirectional. 
Gardner [10] has suggested that drugs of abuse that promote DA signals short circuit and sensitize 
dynamic mesolimbic mechanisms that evolved to attribute incentive salience to rewards. Accordingly, 
Gardner [10] further suggested that addictive drugs have in common that they are voluntarily   
self-administered, they enhance (directly or indirectly) dopaminergic synaptic function in the nucleus 
accumbens (NAc), and they stimulate the functioning of brain reward circuitry (producing the “high” 
that drug users seek). Blum and Gold [11] pointed out that reward circuitry is very complex, especially 
as these circuits relate to hedonic tone. Moreover, these circuits now are believed to be functionally 
more complex, also encoding attention, reward expectancy, disconfirmation of reward expectancy, and Int. J. Environ. Res. Public Health 2011, 8                 
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incentive motivation. Elevated stress levels, together with polymorphisms of dopaminergic genes and 
other neurotransmitter genetic variants, may have a cumulative effect on vulnerability to addiction. We 
and others believe that the RDS model of etiology holds very well for addictions [10]. 
The D2 receptor has been associated with pleasure, and the DRD2 has been referred to as a reward 
gene [9-16].  The DRD2 gene, and especially the Taq1 A1  allele, has been associated with 
neuropsychiatric disorders in general, including alcoholism, other addictions (e.g.,   
carbohydrate)  [17-23], and it also may be involved in co-morbid antisocial personality disorder 
symptoms [24], especially in children and adults with attention deficit hyperactivity disorder (ADHD) 
or Tourette Syndrome [5,25] and high novelty seeking [26-29]. 
DA is involved in a remarkable number of behavioral functions including cognition and motor 
effects [30], depending upon its localization in the brain. DA has been called the “anti-stress molecule” 
and/or the “pleasure molecule”  [2,31-33] and is released into the synapse in the NAc where it 
stimulates a number of receptors (D1–D5), which results in increased feelings of well-being and stress 
reduction. The mesocorticolimbic dopaminergic pathway plays an especially important role in 
mediating the reinforcement of natural rewards like food and sex, as well as unnatural rewards like 
drugs of abuse. Natural rewards include satisfaction of physiological drives (e.g.,  hunger and 
reproduction) [34,35], and unnatural rewards are learned and involve satisfaction of acquired pleasures 
such as hedonic sensations [36,37] derived from alcohol and other drugs, as well as from gambling and 
other risk-taking behaviors [33-36,38,39].  
In discussing RDS, we refer specifically to an insensitivity  and inefficiency in the reward   
system [1-4,40,41]. There may be a common neurocircuitry [42] and neurobiology [43] for multiple 
addictions [44,45] and for a number of psychiatric disorders [43-51]. Due to specific genetic 
antecedents and environmental influences [52],  a deficiency of the D2 receptors may predispose 
individuals to a high risk for multiple addictive, impulsive, and compulsive behaviors [4,31,53-57].  
It is well known that alcohol and other drugs of abuse [58], as well as most positive reinforcers (e.g., 
sex [59], food [60], gambling [61-63], aggressive thrills [6]) cause activation and neuronal release of 
brain DA [32,62,63], which in turn can decrease negative feelings and satisfy abnormal cravings for 
alcohol, cocaine, heroin, and nicotine, and which are linked to low DA function [53,55,56,64-78].  
Since there is a commonality in the mechanism by which drugs of abuse, smoking, food, sex, 
gaming—and their associated cues, e.g., seeing drug paraphernalia—stimulate the release of mesolimbic 
DA at the NAc, it is difficult to determine which, if any, of these RDS behaviors will specifically 
manifest in a family member. However, utilizing a Bayesian mathematical model, we have found that 
at least for carriers of the DRD2 A1 allele, the estimated predictive value is 74% [3]. Simply put, 
having this high predictive value suggests that an individual carrier could transfer one addiction for 
another [3]. In terms of gene expression at the mRNA level, there is specificity for many psychoactive 
drugs [79].  
1.2. Brief Description of Risk Alleles in a Number of Dopaminergic Reward Genes 
Dopamine D2 receptor gene (DRD2).  The DA D2 receptor gene (DRD2) first associated with 
severe alcoholism is the most widely studied gene in psychiatric genetics [19]. The Taq1 A is a single 
nucleotide polymorphism (SNP rs: 1800497) originally thought to be located in the 3'-untranslated Int. J. Environ. Res. Public Health 2011, 8                 
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region of the DRD2 but has since been shown to be located within exon 8 of an adjacent gene, the 
ankyrin repeat and kinase domain containing 1 (ANKK1). Importantly, while there may be distinct 
differences in function, the mis-location of the Taq1 A allele may be attributable to the ANKKI and the 
DRD2 being on the same haplotype or the ANKKI being involved in reward processing through a 
signal transduction pathway [80]. The ANKKI and the DRD2 gene polymorphisms may have distinct, 
different actions with regard to brain function [81]. Presence of the A1
+ genotype (A1/A1, A1/A2) 
compared to the A
–  genotype (A2/A2) is associated with reduced receptor density [82-84]. This 
reduction causes hypodopaminergic functioning in the DA reward pathway. Other DRD2 
polymorphisms such as the C (57T, A SNP (rs: 6277) at exon 7 also associates with a number of RDS 
behaviors including drug use [85]. Compared to the T
– genotype (C/C), the T
+ genotype (T/T, T/C) is 
associated with reduced translation of DRD2 mRNA and diminished DRD2 mRNA, leading to reduced 
DRD2 density and a predisposition to alcohol dependence [86]. The Taq1 A allele is a predictive risk 
allele in families [87].  
Dopamine transporter gene (DAT1).  The DA transporter protein regulates DA-mediated 
neurotransmission by rapidly accumulating DA that has been released into the synapse [88]. The DA 
transporter gene (SLC6A3 or DAT1) is localized to chromosome 5p15.3. Moreover, there is a VNTR 
polymorphism within the 3' non-coding region of DAT1 [89]. There are two important alleles that may 
independently increase risk for RDS behaviors. The 9 repeat (9R) VNTR has been shown to influence 
gene expression and to augment transcription of the DA transporter protein, resulting in an enhanced 
clearance of synaptic DA, yielding reduced levels of DA to activate postsynaptic neurons. Presence of 
the 9R VNTR has also been linked to Substance Use Disorder [87]. Moreover, in terms of RDS 
behaviors, tandem repeats of the DA transporter gene (DAT) [90] have been associated with high risk 
for ADHD in children and in adults alike [91,92]. The 10-repeat allele is significant for hyperactivity-
impulsivity (HI) symptoms [93].  
Dopamine D1 receptor gene (DRD1). Abnormalities in the dopaminergic reward pathways have 
frequently been implicated in substance abuse and addictive behaviors. Recent studies by Self [94] 
have suggested an important interaction between the DA D1 and D2 receptors in cocaine abuse. To test 
the hypothesis that the DRD1 gene might play a role in addictive behaviors  Comings  et al.[95], 
examined the alleles of the Dde I polymorphism in three independent groups of subjects with varying 
types of compulsive, addictive behaviors  Tourette syndrome probands, smokers, and pathological 
gamblers. Specifically, in all three groups there was a significant representation of the frequency of 
homozygosity for the DRD1 Dde I 1 or 2 alleles in subjects with addictive behaviors. The DRD1 11 or 
22 genotype was present in 41.3% of 63 controls and 57.3% of 227 TS probands (p = 0.024). When 23 
quantitative traits were examined statistically, those carrying the 11 genotype consistently showed the 
highest scores. Based on these results, they examined the prevalence of the 11 genotype in controls and 
in Tourette syndrome probands. There was a highly significant progressive, linear increase in scores 
for gambling, alcohol use, and compulsive shopping. Problems with three additional behaviors, drug 
use, compulsive eating, and smoking also were significant. All six variables were related to addictive 
behaviors. In a totally separate group of controls and individuals attending a smoking cessation clinic, 
39.3% of the controls versus 66.1% of the smokers carried the 11 or 22 genotype (p = 0.0002). In a 
third independent group of pathological gamblers, 55.8% carried the 11 or 22 genotype (p = 0.009 
versus the combined controls). In the Tourette syndrome group and in smokers there was a significant Int. J. Environ. Res. Public Health 2011, 8                 
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additive effect of the DRD1 and DRD2 genes. The results for both the DRD1 and DRD2 genes, which 
have opposing effects on cyclic AMP, were consistent with negative and positive heterosis, 
respectively. These results support a role for genetic variants of the DRD1 gene in some addictive 
behaviors, and an interaction of genetic variants at the DRD1 and DRD2 genes.  
Volkow’s group [96], using in vivo optical microprobe imaging, tested the role of DA D1 receptors 
relative to DA D2 receptors during acute cocaine administration. Their results suggested that since 
activation of striatal D1R-expressing neurons (direct-pathway) enhanced cocaine reward, whereas 
activation of D2R-expressing neurons suppressed it (indirect-pathway), cocaine’s rewarding effects 
entailed both its fast stimulation of D1R (resulting in abrupt activation of direct-pathway neurons) and 
a slower stimulation of D2R (resulting in longer-lasting deactivation of indirect-pathway neurons). 
Lobo et al. also provided direct in vivo evidence of D2R and D1R optogenetic interactions in the 
striatal responses to acute cocaine administration [97]. 
Dopamine beta-hydroxylase gene (DBH). DA β-hydroxylase (DBH) is a membrane-bound enzyme 
that converts DA to norepinephrine, thereby making norepinephrine and epinephrine the only 
transmitters synthesized inside vesicles (http://en.wikipedia.org/wiki/Dopamine_beta_hydroxylase). It 
is expressed in noradrenergic nerve terminals of the central and peripheral nervous systems, as well as 
in chromaffin cells of the adrenal medulla. Even prior to the emergence of the neuropsychogenetic 
field and candidate gene analysis was begun, Egeland identified a possible link to manic-depressive 
disorder and the tyrosine hydroxylase enzyme [98]. Subsequently, Comings and his colleagues [99] 
associated the DBH gene polymorphism with ADHD. Polymorphisms of three different dopaminergic 
genes, DA D2 receptor (DRD2), DBH, and DA transporter (DAT1), were examined in Tourette 
syndrome probands, their relatives, and controls. Each gene individually showed a significant 
correlation with various behavioral variables in these subjects. The additive and subtractive effects of 
the three genes were examined by genotyping all three genes in the same set of subjects. For nine of  
20 Tourette syndrome associated comorbid behaviors, there was a significant linear association 
between the degree of loading for markers of three genes and the mean behavior scores. The behavior 
variables showing the significant associations were, in order: ADHD, stuttering oppositional defiant, 
tics, conduct, obsessive-compulsive, mania, alcohol abuse, and general anxiety. These are behaviors 
that constitute the most overt clinical aspects of Tourette syndrome. For 16 of the 20 behavior scores, 
there was a linear progressive decrease in the mean score, with progressively lesser loading for the 
three gene markers.  
In a recent PUBMED search, we coupled the terms DBH and ADHD, and we found 39 citations; 
the findings were both positive and negative. An interesting noteworthy example involves the work of 
Hess  et al.  [100]. Their findings did not implicate the DBH C-1021T polymorphism in the 
pathophysiology of depressive disorders or personality disorders, yet homozygosity at this locus 
appeared to increase the risk towards personality traits related to impulsiveness, aggression, and 
related disease states. In 2008, others [101] reported for polymorphisms G444A and C1603T in DBH, 
which were detected by univariant analysis, haplotype resulted in showing that the risk of ADHD was 
significantly increased in the presence of allele DBH +444A, as well as in the presence of allele DBH 
+1603T (O.R. = 15). Specifically, Barkley et al. [102] found that the DBH TaqI A2 allele, when 
homozygous, was associated with increased hyperactivity in childhood, pervasive behavior problems 
at adolescence, and earning less money on a card-playing task in adulthood. At adolescence, poorer Int. J. Environ. Res. Public Health 2011, 8                 
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test scores were also found only in the hyperactive group, which was homozygous for this allele. 
Similar associations with ADHD related behaviors have been reported by others [62,76,103], as well 
as in a meta-analysis showing the association of DBH and ADHD etiology [100]. Moreover, 
McKinney et al. [104] found that polymorphisms of DBH and MOA predicted whether a person was a 
heavy smoker and how many cigarettes they consumed. The findings of McKinney et al. [104] support 
the view that these enzymes help to determine a smoker’s requirement for nicotine and may explain 
why some people are predisposed to tobacco addiction and why some find it very difficult to   
stop smoking.  
We report here the results of the first intra-generational family association study, concerning a 
sampling of dopaminergic polymorphisms, utilizing a generalized RDS set of behaviors as the 
“phenotype” (see Table 1 defining thirds phenotype) rather than any single select phenotype, as well as 
a group of “super normal” control subjects. Super controls have been extensively screened for many 
associated RDS behaviors as defined herein (see below). Our results provide sufficient evidence to 
support a new approach to the study of Reward Deficient aberrant behaviors. 
Table 1. Examples of behaviors and disorders [1-4,11,12,27,32,33,105-114, 
116-140,185,186,196,210,213] associated with Reward Deficiency Syndrome. 
ADDICTIVE BEHAVIORS: Alcoholism; Drug Abuse; Smoking; Compulsive Eating and Obesity 
IMPULSIVE BEHAVIORS: Attention Deficit Disorder; Attention Deficit Hyperactivity Disorder; Autistic Disorders; 
Tourette Syndrome 
COMPULSIVE DISORDERS: Hypersexuality and Aberrant Sexual Behaviors; Pathological Gambling and  
Internet Gaming 
PERSONALITY DISORDERS: Antisocial Personality Disorder; Conduct Disorder; Pathological Aggression; 
Generalized Anxiety Disorder 
2. Methodology  
Although other neurotransmitter systems are involved in these complex behaviors representative of 
polygenic inheritance, we decided to evaluate the potential association of certain polymorphisms of the 
DA: D1 receptor (DRD1), DA D2 receptor (DRD2) [rs1800297 as a RFLP in “DRD2”] which it is 
near in the 3'-untranslated region contains ANKK1 on the opposite strand of DNA and our method 
herein targets the same site], DA transporter (DAT1), and DBH genes. To that end, we genotyped  
55 subjects, from two independent multiple-affected families with documented RDS behaviors. There 
were four generations (Family A—initial proband was identified with ADHD) and five generations 
(Family B—initial probands was identified with substance use disorder). We had postmortem data 
related to RDS behaviors on all the deceased family members. A total of 13 members died, and their 
respective DNA specimens were not available. Figure 1 illustrates the genotyping and self-reported 
and family-identified behaviors for each family member. 
2.1. Subject Selection  
All individuals were evaluated through structured interviews using DMS-IV criteria and a number 
of neuropsychological and electrophysiological tests (e.g., Meyer-Briggs, Millon, TOVA, qEEG, etc.). Int. J. Environ. Res. Public Health 2011, 8                 
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The “super” control group consisted of 30 individuals selected from a total of 189 people attending 
PATH Medical Clinic, an integrative care center and research foundation in New York City, for both 
neurological and non-neurological problems (for more details, see [105]).  These individuals were 
carefully screened, including their family history to exclude a number of RDS-related behaviors. The 
excluded behaviors included but where not limited to: alcoholism, substance use disorder, smoking 
behavior, carbohydrate binging, obesity, ADHD,  posttraumatic stress disorder, conduct disorder, 
antisocial behavior, pathological gambling, aggressive offenses, pathological aggression, deviant 
sexual behavior, schizoid/avoidant behavioral cluster, and other Axis 1 and Axis 11 mental disorders. 
These subjects were genotyped for only the DRD2 gene polymorphisms (A1/A1, A1/A2. and A2/A2). 
In addition,  we also  genotyped  91 lesser screened controls (excluding only ADHD, pathological 
aggression, alcohol, tobacco, and other drug abuse and dependence) for the DAT1 9 and 10 alleles. 
Among these lesser-screened controls, 61 had DRD1 genotyping for the A1/A1, A2/A2, and A1/A2 
alleles, and 51 had DBH genotyping for the B1/B1, B1/B2, and B2/B2 alleles. The study protocol was 
approved by the PATH Foundation IRB and ethics committee,  and participants  signed  approved 
informed consent forms.  
The experimental group consisted of 55 individuals from two independent families. Family A was 
provided for analysis by the Southeastern Biofeedback and Neurobehavioral Clinic, Knoxville, TN, 
and Family B was provided for analysis by the Enhancement Institute, Houston, TX (Unique Mind 
Care. Inc.) RDS diagnosis was available on 42 members from four generations of Family A (Figure 1) 
and 26 members from five generations of Family B (Table 2 and Figure 2).  These included 10 
deceased Family A members and three deceased Family B members. A total of 32 Family A and 23 
Family B individuals were genotyped. In Family A, there were a total of 14 males and 18 females 
genotyped at an average age of 31.6 ± 18.9 years, and for Family B there were nine males and 14 
females genotyped with average age of 31.5 ±  24.2 years. The members of Family A had been 
diagnosed with ADHD, and the members of Family B had been diagnosed with substance use disorder. 
The RDS behaviors observed included alcoholism, cocaine dependence, marijuana abuse, intravenous 
drug dependence, carbohydrate binging, obesity, smoking, hyperactivity, sex addiction, pathological 
aggression, Tourette syndrome, autism, criminal activity, gambling, novelty seeking, and personality 
disorders (see Figures 1 and 2). 
2.2. Genotyping 
Buccal epithelial cells were collected by cotton swabs for DNA isolation. In some subjects, a blood 
sample was obtained. In this study we isolated the DNA and analyzed a number of genes. The genes 
include DRD1, DRD2, DAT1 and DBH. All subjects were genotyped based on a neutral identification 
number and read without knowledge of the individual being typed. Total genomic DNA was extracted 
from each coded blood/buccal sample, and aliquots were used for polymerase chain reaction (PCR) 
analysis. Genotyping was performed by a PCR technique. PCR was performed in 30-µL reaction 
mixtures containing 1.5  mM  MgCl2,  2  mM  2'-deoxynucleotide 5'-triphosphates (dNTPs), 0.5  µM 
primers, 1 µg of template DNA 1, 5 U of Taq polymerase (Boehringer Mannheim Corp., Indianapolis, 
IN, USA), and PCR buffer (20 mM Tris-HCL (pH 8.4) and 50 mM KCL. After an initial denaturation Int. J. Environ. Res. Public Health 2011, 8                 
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at 94 °C for 4 minutes, the DNA was amplified with 35 cycles of 30 seconds at 94 °C, 30 seconds at  
58 °C, and 30 seconds at 72 °C, followed by a final extension step of 5 minutes at 72 °C. 
Figure 1. Genotype results of the Dopamine D2 receptor gene (DRD2) polymorphism of 
family A (n = 32) identified with multiple Reward Deficiency Syndrome (RDS) behaviors. 
 
 
Dopamine D2 receptor gene.  The  oligo-nucleotide primers 5'-CCGTCGACCCTTCCTGAGT-
GTCATCA-3' and 5'-CCGTCGACGGCTGGCCAAGTTGTCTA-3' were used to amplify a 310-base 
pair fragment spanning the polymorphic TaqA1site of the DRD2 gene. The D2A1 and D2A2 
genotyping was performed by a PCR technique. The PCR product was digested with 5 U of Taq 1 for 
22 hours at 65  °C for the Taq1A polymorphism. Digestion products were then resolved on a   
3% agarose gel (5 V/cm) containing 0.65 µg/mL ethidium bromide. There were three DRD2 Taq1A 
genotypes: the predominant homozygote A2/A2, which exhibits three restriction fragments of 180 and 
130 bp; the heterozygote A1/A2, which exhibits three restriction fragments of 310, 180, and 130 bp; 
and the rare homozygote A1/A1, which produces only the uncleaved 310-bp fragment [20]. 
Dopamine transporter gene. DAT1 was genotyped by the technique of Comings et al. [5].  
Dopamine D1 receptor gene. To examine the DRD1 gene we utilized the Dde I polymorphism 
consisting of an A to G change in the 5’  UTR, tested by the PCR procedure described by   
Thompson et al. [106].  
 Int. J. Environ. Res. Public Health 2011, 8                 
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Dopamine beta-hydroxylase gene.  For DBH, the Taq  I  B polymorphism was genotyped  by the 
technique of d’Amato et al. [107].  
Figure 2. Association of dopaminergic gene  polymorphisms with RDS behaviors in 
Family B (n = 23). 
 
2.3. Statistical Analyses 
Demographic, clinical, laboratory, interview, and questionnaire data were coded and entered into a 
computer database. DRD1, DRD2, DAT1 and DBH allelic prevalence, obtained by personnel blinded 
to the aforementioned information, also was coded. All comparisons were based on 2 × 2 contingency 
tables. Pearson’s chi-square statistic was used to identify group differences, with p < 0.05 considered 
statistically significant. In cases where at least one cell of the 2 × 2 contingency table had an expected 
frequency less than 5, Yates’ correction for continuity [108] was applied. To indicate the increase in 
odds of being gene positive for the experimental group relative to controls, odds ratios with 95% 
confidence intervals also  were calculated. Group sample size of 55 for RDS and 30 for controls 
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achieve 93% power to detect an odds ratio in the group porportions of 5.00 or more at the 0.05 level. 
All statistical analyses were performed using SPSS statistical software (SPSS, Inc., Chicago, IL, USA).  
3. Results  
3.1. Genotyping 
Dopamine D2 receptor gene. A large percentage (78.2) of the experimental subjects (43 of 55) 
carried the DRD2 Taq A1 allele. When compared with “super controls,” (1/30 or 3.3% of the controls 
carried the DRD2A1 allele), the experimental rate was significantly greater (χ
2 = 43.6, p < 0.001) with 
an odds ratio of 103.9 (12.8, 843.2). Similarly, with regard to the DRD2 gene, when the experimental 
group (n = 55) was compared with unscreened literature controls derived from 15 international studies 
(LCN) [LCN =  439/3,329 (31.32%)], the experimental  rate was significantly greater (χ
2  =  187.1,  
p < 0.001) with an odds ratio of 23.6 (12.3, 45.1) (Table 2). Since the gene positive rate for Family B 
was lower than that for the combined families, separate experimental vs. control comparisons were 
made using Family B alone. When compared to “super controls”, Family B had a significantly greater 
positive rate (χ
2 = 14.7, p < 0.001) with an odds ratio of 26.6 (3.1, 229.3), and a similar result was 
found when compared to unscreened literature controls (χ
2 = 20.7, p < 0.001) with an odds ratio of  
6.0 (2.6, 13.8). Based on over 3,000 unscreened subjects, the A1 allele of the DRD2 gene is present in 
approximately one-third of the American population, whereas the A2 allele is present in two-thirds of 
the American population [9].  
Dopamine transporter gene. We found the less rigorous (no ADHD, alcoholism, substance abuse) 
91 screened controls to carry the DAT1 10/10 in 34 subjects (37.4%); the 9/10 in 40 subjects (44.0%) 
and the 9/9 in 12 subjects (13.2%). With regard to the DAT1 gene, the 10/10 allele was present in 32 of 
55 (58.2%) experimental group individuals in the two families. The experimental positive rate for the 
10/10 allele was significantly greater (χ
2  =  6.0, p  <  0.015) with an  odds ratio of 2.3 (1.2, 4.6). 
Moreover, 19 of the 32 probands (59.4%) from Family A (four generations) that were genotyped for 
the DAT1 gene carried the 10/10 allele, so that Family A had a significantly greater positive rate   
(χ
2 = 4.7, p < 0.035) compared to controls with an odds ratio of 2.5 (1.1, 5.6). In Family B, 57.5%  
(13 of 23) carried the 10/10 genotype (Table 2 and Figure 1), but owing to the smaller sample size, the 
Family B positive rate was not significantly different (χ
2 = 2.8, p = 0.095) from controls. Based on 
genotype data for the DAT1 gene on 3,080 subjects, the 480 bp 10/10 allele occurs in approximately 
55% of the unscreened American population; the 9/10 occurs in approximately 38% of unscreened 
Americans; and the rare 9/9 allele occurs in 7% of unscreened Americans [5].  
Dopamine D1 receptor gene. Because Comings et al. had shown the DA D1 receptor gene to be 
associated with substance use disorder [95], we analyzed this gene in Family B. When we compared 
subjects in Family B genotyped for polymorphisms of this gene with 61 controls, we found that in the 
Family B probands, 65.2 % carried the A1/A2 (15/23), 26.1% the A2/A2 (6/23), and 8.7% the A1/A1 
(2/23) genotype (combined homozygosity A1/A1 and A2/A2 = 34.8%). When we compared the 
experimental homozygosity genotyping result against the 61 controls, for which three (4.9%) were 
positive for A1/A1, 20 (32.8%) were positive for A2/A2, and the combined homozygosity (A1/A1 and 
A2/A2)  rate was 37.7%, no significant differences were observed (p  >  0.50). In the American Int. J. Environ. Res. Public Health 2011, 8                 
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population, genotyping data revealed that 6% carry the A1/A1 allele (moderately dysfunctional); 35% 
carry the A2/A2 allele (severe dysfunction); and 60% carry the A1/A2 allele (normal) [5].  
Dopamine beta-hydroxylase gene. Comparing the percent prevalence of the DA Beta-hydroxylase 
gene (DBHB1) in 51 controls [52.9 % (27/51]] with the 32 members genotyped only in Family A [65% 
(21/32)], DBHB1 was not significantly different (χ
2 = 1.3, p > 0.25) (see Table 2). Since we found no 
significance with this gene in Family A, we decided not to test it in Family B. In the unscreened 
American population, genotyping data revealed that 21% carry the B1/B1 genotype, 69% carry the 
B1/B2 genotype and 58% carry the  B2/B2 genotype [23,99]. However, the percentage decreases   
when one screens for no alcohol, drug or tobacco abuse/dependence (B1/B1 = 6%; B1/B2 = 21%;  
B2/B2 = 24%).  
3.2. Findings and Their Implications  
Table 2 summarizes the genotype results for dopaminergic genes in Families A and B. The results 
for each gene polymorphism are presented.  
Table 2. Genotype results for dopaminergic genes in Family A and Family B. 
Gene and 
Polymorphism 
Percent Prevalence in 
Non-RDS Group 
Percent Prevalence in 
Super Control Group 
Percent Prevalence 
in RDS Group 
Significance 
level p Value 
DRD2-A1 Allele  31.32 (n = 3,143) *  3.3 (n = 30) ** 
78.2 (n = 55) 
Family A and B 
* p < 0.001 
** p < 0.001 
DAT1-10/10 Allele  37.4 (n = 91) *  Not Applicable 
58.18 (n = 55) 
Family A and B 
*p < 0.015 
DBH-B1 Allele  52.9 (n = 51)  Not Applicable 
65.0 (n = 32) 
Family A 
Not significant 
DRD1-A1/A1  65.2 (n = 61)  Not Applicable 
31.0 (n = 23) 
Family B 
Not significant 
 
Evaluating severity: Genetic Addiction Risk Score (GARS). Interestingly, in Family A, 100% of the 
subjects had at least one dysfunctional dopaminergic polymorphism. However, in considering the role 
of dopaminergic gene polymorphisms in RDS behavior, unlike Family A, where 100% of the subjects 
carried the DRD2 A1 allele, in Family B only 47.8% carried the TaqA1. Therefore, for Family B only, 
we evaluated severity by utilizing a Genetic Addiction Risk Score (GARS), a multivariate genetic 
index score methodology (developed by LifeGen, Inc. and Dominion Diagnostics, Inc.; see [109]) to 
strengthen the predictive value of laboratory testing for genetic predispositions related to disease 
diagnosis, stratification, prognosis, metabolism, and nutritional response. In this regard, the breakdown 
of the polymorphic markers was as follows: two subjects carried three polymorphic markers;   
13 subjects had two polymorphic markers and eight subjects carried one polymorphic marker.  
4. Discussion  
4.1. RDS, a Putative Endophenotype: Multiple Behaviors versus a Single Subset  
In doing association studies for which an investigator requires a representative control sample for a 
single RDS psychiatric diagnosis [18,22,24,110-112] or for potential subsets of RDS (see Table 3), the Int. J. Environ. Res. Public Health 2011, 8                 
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obvious limitation relates to controls poorly screened for multiple RDS behaviors and other related 
psychiatric disorders. 
Missing behaviors that are part of the RDS subset may be the reason for spurious results [9,87, 
113-117] when genotyping for single subsets of RDS behaviors. For example an individual may not 
drink or use drugs but may have other RDS behaviors like overeating or intensive video gaming. In 
support of this notion, we found a very strong association of the DA D2 receptor A1 allele (100%) in 
Family A. In addition, every individual in Family B also has at least one dopaminergic high risk allele 
(100%) [48% carried the DRD2 A1 allele]. Moreover, in Family B only three adult individuals had no 
addictive behaviors. When we compared our results in which 55 RDS subjects carried the DRD2 A1 
allele at (78.2%) with the results of research by Noble [14] in which 597 severe alcoholic-dependent 
individuals (49.3%) carried the A1 allele, there was a significant difference between these two groups 
(χ
2 = 16.9, p < 0.001). This demonstrated that the A1allele prevalence increases with multiple RDS 
behaviors. Here we propose that multifaceted non-specific RDS behaviors should be considered as the 
true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. 
Indeed, this may be a paradigm shift in future association and linkage studies using a different set of 
statistical methodologies. 
Table 3. Correlation of RDS and related neurological and psychiatric disorders with DRD2 
SNP (a sampling).  
Reward Deficiency Syndrome or Related Disorder 
Studies Demonstrating an Association with 
DRD2 Gene Polymorphism(s) 
Pathological Gambling  [4,5,33,61-64,140] 
Attention Deficit Hyperactivity Disorder  [2,4,24,99,154,196,207-210]  
Post-Traumatic Stress Disorder  [4,176,177,196,212,213]  
Eating; Obesity and Related Sequela  [46,133,134,170,178,179,181,182,197,198,200] 
Energy Production  [134,180] 
Hypertension  [181,182] 
Schizophrenia  [12,19,49,112,183] 
Early-Onset Sexual Intercourse; Hyper sexuality  [136,203] 
Anti-Social Personality  [18,53] 
Pathological Aggression  [6,105 ,171,186] 
Schizoid-Avoidant Behavior  [143] 
Novelty or Sensation Seeking  [26,27,36,83,109,113,144,161] 
Substance Abuse 
[12,13,20,22,29,46,65,71,90,103,110,114,117, 
172-175,193,199,201,202,205]  
Heroin Addiction  [13,48,66,111,160] 
Nicotine Dependence and Smoking Behavior  [13,17,22,81,91,104,184,185] 
Personality Disorders and Crime  [100,186] 
Parkinson’s Disease  [187,188] 
Migraine  [189] 
Tourette Syndrome  [5, 99,190] 
Huntington’s Disease  [191] 
Cell Metabolism  [47] 
Major Psychoses & Affective Disorder  [192,195,204] 
Extraversion and Creativity  [21,23,145] Int. J. Environ. Res. Public Health 2011, 8                 
 
4438 
4.2. “Super” Controls as a Phenotype: Exclusion of Multiple RDS Behaviors  
For population-based studies in which the investigator requires a representative control sample, 
removing  confounding cases from the control  group may improve chances of finding significant 
differences between experimental and control groups. This approach, however, may risk a  lack of 
representation in the control group. Even the use of stratified samples (weighting samples) may not be 
good enough [113-116]. 
In the case of finding a “pure” phenotype, especially in the psychiatric arena, we really do not know 
if nature carved out the psychiatric disorders in the same fashion as is seen in the DSM. This is true 
because behavior is very complex, whereby specific genes for behavioral tendencies (anxiety, 
impulsivity, compulsivity, harm avoidance, aggressiveness, addiction etc.) accounts for only a small 
risk contribution to the overall phenotype. Therefore, we must shift our emphasis to the “systems 
biological” approach, which takes into account the inter relationship of dysfunctional behaviors, the 
polygenic nature of psychiatric disorders, and the environment.  
We should consider the established concept of RDS [1-4] to help define this complex array of 
behaviors associated with molecular dysfunctions. Victims of RDS are at increased vulnerability to 
addictive activities because they may carry polymorphic genes in dopaminergic pathways [117-122] 
that result in hypo-dopominergic function [60-62]  caused by  a reduced number of DA D2   
receptors [55,117,118], reduced synthesis of DA (DA beta-hydroxylase) [5], reduced net release of  
pre-synaptic DA, possibly due to altered synthesis of DA (L-amino-acid decarboxylase) [123], 
increased synaptic clearance due to a high number of DA transporter sites [92-94,118,120-122] (DA 
transporter), and low D2 receptor densities [55,56,85,123-127] (DA D2 receptor). The need for a 
unified set of related symptoms in the affected phenotype is important not only for population-based 
association studies, but also for linkage analysis. The  RDS concept  involves,  shared genes and 
behavioral tendencies  as summarized in Table 3.  While  poly-genes  are  involved [128-145],  the 
common theme in all of these substances and behaviors is that they induce pre-synaptic DA release at 
the NAc [53,73-77]. Spectrum disorders such as ADHD, Tourette Syndrome, and autism are included 
due to DA dysregulation [1,5,24,25]. In fact love styles also associate with both serotonergic and 
dopaminergic gene polymorphisms [146].  
A screened control group is essential for uncovering population-based associations where the 
disease in question may be very common. We know that approximately one-third of the population 
meet lifetime criteria for common psychiatric disorders according to the results of the Epidemiological 
Catchment Area survey. Since RDS is a “polygenic disorder” involving multiple genes and many 
polymorphisms [1-4] and  requires  a threshold number of polygenes, unaffected individuals in the 
population also carry some of these genes. AS stated earlier, the DA D2 receptor gene (A1 allele)  
is present in about one-third of unscreened Americans (29.4% in 3,329  subjects studied up until   
2003) [14].  
The use of super controls has been criticized by some on the grounds that their relatives will have 
rates of co-morbid  disorders lower than that in the general population and may produce spurious   
co-aggregation of disorders within families. This argument is valid only if the same psychopathology 
that is removed from the control group is not excluded from among the probands and their relatives.  Int. J. Environ. Res. Public Health 2011, 8                 
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This provides the rationale to encourage others to begin to carefully select true controls   
especially when dealing with complex traits such  as RDS involving a number of associated gene  
polymorphisms [88,147-149].  
Very few behaviors depend upon a single gene. Complexes of genes (polygenic) drive most of our 
heredity-based actions [150-154], suggesting that genetic panels or algorithms organized into genetic 
indexes, such as GARS may be valuable clinically to determine risk. Certainly abnormal   
functions of these brain systems can be due to specific genetic factors interacting with environmental  
factors [118-120,122,149,150,152-154]. Understanding the interactions of these components is likely 
to lead to better treatment. 
Because our study began in 1999 when less was known about dopaminergic genes, we did not 
genotype subjects for the following: D3–5 receptor genes, the MAO-A or MAO-B, or catechol O-
methyltransferase. However, those will be analyzed in subsequent experiments. When we started these 
experiments, the specific roles of the dopaminergic genes in brain function remained inconclusive due 
to the lack of completely selective ligands that could distinguish between the members of the D1-like 
and D2-like DA receptor families. However, today we are making rapid progress distinguishing among 
the various DA receptors (see [96]). Our findings, while suggestive, must be interpreted with caution. 
In terms of inclusion/exclusion criteria, since this was a generational study, all subjects were included 
in the study without bias. 
4.3. Interactive Environmental and Genetic Roles in RDS Behaviors  
It is important to consider one of the most important new areas in neurobiology and genetics termed 
“epigenetics” and its role in RDS. Most recently, our group reviewed the epigenetics of ADHD and 
detailed the important interaction of environmental elements and gene expression [154]. We are 
cognizant of the simple mathematical equation P = G + E. whereby, any phenotype (RDS included) is 
equal to both one’s genome and environmental impact. The role of the contribution of genetics to illicit 
drug abuse was evaluated by van den Bree et al. [155] using structural equation, modeling genetic and 
environmental estimates and DSM-III abuse/dependence for sedatives, opioids, cocaine, stimulants, 
and cannabis, as well as any other illicit drugs.  The authors found genetic influences for most 
measures, which were strongest for males and for clinical diagnoses of abuse/dependence compared to 
actual substance use. Most interestingly, common environmental influences played a greater role in use 
than abuse/dependence, suggesting that the severity of any RDS behavior may have a stronger genetic 
contribution relative to less severe forms. Moreover, this same group [156] in another study, among 
Caucasians with alcohol dependence characterized subtypes by differential loading on three 
dimensions: genetic, general environmental, and dyssocial environmental symptom scales. The mild 
subtype (60% of men and 66% of women) was distinguished by low mean scores on all three scales; 
the dyssocial subtype (24% of men and 20% of women) by low mean genetic and general 
environmental scores but high mean dyssocial environmental scores; and the severe subtype (16% of 
men and 14% of women) by high scores on the genetic and general environmental scales. Importantly, 
the severe subtype showed greater comorbid drug dependence and major depression, more treatment 
seeking, and a higher prevalence of parental alcoholism. Only the severe subtype showed a pattern of 
scale scores and clinical characteristics suggestive of substantial genetic influence.  Int. J. Environ. Res. Public Health 2011, 8                 
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It is well known that environmental cues may induce relapse in drug dependent individuals. This 
phenomenon has been evaluated by Gerasimov et al. [157] to better understand the neurochemical 
mechanisms potentially mediating these cues by measuring NAc DA levels in animals exposed to 
environmental cues previously paired with cocaine administration. They found that in animals exposed 
to a cocaine-paired environment, NAc DA increased by 25%. In one study the intake of morphine 
altered the neurotransmitter turnover of DA differentially as function of passive compared non-passive 
infusion. Environmental contingent infusion compared to passive infusion of intravenous morphine 
significantly affected more brain regions up to 5 fold [158] suggesting impact of the environment on 
neurochemistry. The role of dopaminergic genes as a predictor of risk concerning personality traits has 
been positively identified in molecular genetic studies. Earlier work in our laboratory identified the 
relationship between schizoid avoidance [143] as well as impulsive and compulsive behaviors [159]. 
The work of The et al. [160] showing significantly higher frequency for the DRD2 TaqIA polymorphism 
among  addicts (69.9%) compared to control subjects (42.6%; Fisher’s exact χ
2, p < 0.05) is in 
agreement with our earlier findings. They also observed that the studied addicts had higher scores for 
novelty seeking and harm avoidance personality traits but lower scores for reward dependence when 
compared to control subjects. This has been further supported by the work of Kazantseva et al. [161] 
on personality traits in a sample of 652 healthy individuals (222 men and 430 women) of Caucasian 
origin (233 Russians and 419 Tatars) from Russia. The subjects’ personality traits were assessed with 
Eysenck Personality Inventory and the Temperament and Character Inventory-125). There were 
significant effects of ANKK1/DRD2 Taq1A on Neuroticism (p = 0.016) and of SLC6A3 rs27072   
on Persistence (p  =  0.021) in both genders. The association between ANKK1/DRD2 Taq1A   
A2/A2-genotype and higher Novelty Seeking and lower Reward Dependence was shown in men only. 
Genetic and environmental influences also are important for the development of alcohol and drug 
dependence. Exposure to early life stress, has been shown to predict a wide range of psychopathology, 
including addiction. Enoch [162] has suggested that early life stress can result in permanent 
neurohormonal and hypothalamic-pituitary-adrenal axis changes, morphological changes in the brain, 
and gene expression changes in the mesolimbic DA reward pathway, all of which are implicated in the 
development of addiction. However, he further emphasized that a large proportion of children who 
have experienced even severe early life stress do not develop psychopathology, indicating that mediating 
factors such as gene-environment interactions and family and peer relationships are important for 
resilience. Most interestingly, Israel researchers Raz and Berger [163] published convincing evidence 
for the role of social interaction as it related to intake of morphine in animals. Specifically, adult 
Wistar rats housed in short-term isolation (21 days) consumed significantly more morphine solution 
(0.5 mg/mL) than rats living in pairs, both in one-bottle and in two-bottle tests. They also found that as 
little as 60-min of daily social-physical interaction with another rat was sufficient to completely abolish 
the increase in morphine consumption in socially restricted animals. Accordingly, these results indicate 
that environmental and situational factors influence drug intake in laboratory rats as they do in humans. 
Over many years of study, the consensus of the literature has suggested that prevention of   
drug-seeking relapse could be attenuated by enriched environments. For example, a recent French 
study  by  Chauvet  et al. [164] showed, in animals, the potential “curative”  influence  of  enriched 
environments in reducing cocaine-induced craving effects, thereby highlighting the importance  of 
positive life conditions in facilitating abstinence and preventing relapse to cocaine addiction. Int. J. Environ. Res. Public Health 2011, 8                 
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There is no doubt that enriched life experiences, as well as reduced early prenatal and post natal 
stress, have impacts on impulsivity. In addition, reduced release of mesolimbic DA affected both by 
genes and by the environment, play a significant role in craving behavior and more importantly in 
relapse [165-169] as well as many RDS behaviors [170-193]  
4.4. From Bench to Bedside: Clinical Utility of RDS 
Historically, addictive disorders were categorized by the drug the patient was abusing, rather than 
the underlying neurocontrol circuitry that was being affected [194]. Alcohol and drug dependent 
individuals were considered to differ so substantially that treatment programs, as well as funding 
sources and regulatory agencies were distinct and separate. If insurance coverage was available, it was 
often restricted to the treatment of alcoholism, so that drug addicts often lied about their drug of choice 
in order to get admitted. Some methadone maintenance programs allowed drug addicts to drink, 
despite the fact that the leading cause of death at that time prior to viral infections was alcoholic 
cirrhosis. Self-help groups were organized around the drug of choice, such that if a person with a drug 
problem went to an Alcoholics Anonymous (AA) meeting, they were told that the meeting was for 
alcoholic-dependent individuals only and were asked to leave. Many polysubstance abusers who 
attended AA because they could not relate to Narcotics Anonymous (NA), learned not to volunteer 
their drug history. Patients on buprenorphine or methadone are still refrained from sponsoring or 
speaking at NA meetings, secondary to the belief that they are not abstinent (http://www.na.org/?ID= 
bulletins-bull29).  
Over the last 30 years the situation has improved because of our understanding of multiple addictive 
disorders as a brain disease [195-206]. Many programs have some treatment content on the medical 
aspects of addiction, although often it remains as an add-on without explicit integration into the other 
treatment suggestions. Often these presentations are provided by non-physicians in a treatment system 
that lacks a physician component in their multidisciplinary team, or depends upon medical referral to 
another agency or provider. 
Only a handful of treatment centers have utilized the neurobiology of addiction as an integral part 
of patient education with explicit integration of RDS into all treatment content especially as it relates 
ADHD, Posttraumatic stress disorder and drug dependence [207-213]. This section of this paper will 
share how RDS can assist in patient education and acceptance of treatment recommendations including 
participating in self help and use of medication assisted therapy. These recommendations are organized 
around the American Society of Addiction Medicine’s (ASAM) six dimensions of care [214] and by 
treatment chronology. 
ASAM’s  six  dimensions help to classify and assess treatment need and placement. They are: 
intoxication and withdrawal potential; biomedical conditions and complications; emotional behavioral 
conditions and complications; readiness for change; relapse potential; and recovery environment. 
Dimension 1 includes the substance use history, the extent of tolerance and physical dependence and 
the extent of polysubstance use. Clinicians are concerned about the extent of neuroadaptive changes 
and the severity of the addiction, but patients usually focus upon their drug of choice as the primary 
focus of intervention. We frequency hear from patients, “I came here to stop using cocaine, not alcohol 
and marijuana”. By reviewing the anatomy of control circuitry, the common pathway of DA release, Int. J. Environ. Res. Public Health 2011, 8                 
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and the concept of RDS as an inherited and acquired change in sensitivity and calibration of control 
circuitry, patients can now move from viewing the treatment providers as prohibitionists to seeing their 
concerns as medically based. Showing how DA increases in the NAc after natural rewards and by use 
of alcohol and drugs, patients understanding of the risk of cross addiction improves. Warning patients 
about continued use of substances that affect reward circuitry is coupled with drug testing to measure 
patient treatment adherence, especially when the program is providing detoxification and stabilization 
during early recovery. Documenting by patient history and drug testing that many patients have 
simultaneous poly substance use and dependence will allow for the program to document the medical 
necessity for testing and the choice of expanded panels to capture patients attempting to continue drug 
use that is not detectable by traditional testing. When testing for synthetic cannabinoids became 
available, we found that over 50% of patients in our adolescent IOP were getting high despite negative 
THC levels.  
Because of the high percentage of patients with co-occurring disorders (ASAM Dimension 2, 
medical, and Dimension 3, emotional/behavioral  conditions and complications), use of RDS as a 
primary treatment concept allows patients to understand their biological differences and the role of 
inheritance. Over 80% of patients in our outpatient program have a positive family history of 
alcoholism and drug addiction, and often as children promised themselves that they would not grow up 
to be like their parents. Other patients suffer from binge eating, compulsive gambling, “shopaholism”, 
etc. A strong emphasis on the genetic aspects of RDS assists the patient in reducing guilt and shame 
and understanding how they could become something that they never planned on. This strengthens the 
importance of not over-relying on willpower and learning as primary treatment methods, and provides 
a medical justification of the counselors and sponsors recommendations. Acknowledging patients’ 
anhedonia during early recovery and incorporating thoughts, feelings and behaviors that increases 
reward, provides a therapeutic alliance and a potential acceptance by patients of treatment 
recommendations for proper nutrition, exercise, medications and other enjoyable activities. 
By explaining the association with other disorders, RDS allows for the program and the patient to 
utilize standardized screening techniques for conditions such as ADD, gambling, aberrant sexual 
behavior as well as for personality profiles of aggressive and antisocial behaviors. Diagnosing patients 
with an associated condition(s) allows for education and early treatment. We have frequently observed 
impulsive behavior result in relapses during early recovery, as well as interfering with the quality of 
life and improved workplace functioning. Treating ADD earlier in recovery can be challenging, 
especially if the patient is focused upon becoming drug free and views any medications for ADD as 
part of the addictive process. Explaining how early treatment can help restore neurochemical balances 
provides a medical explanation that differentiates getting high from experiencing improved reward 
responsiveness to natural stimuli. 
Not only is RDS helpful for the problems associated with ASAM Dimensions 1 through 3, but it 
also is most important in educating the patient about their disease (ASAM Dimension 4) and directly 
confronting altering cognition and defense mechanisms such as denial, rationalization, and 
justification. By explaining the pathophysiology of RDS, patients’ understanding of their illness 
improves significantly, especially in appreciating the subtle details of therapists’ recommendations. It 
is important for clinicians to explicitly connect RDS concepts with AA sayings and slogans so that the 
patient can understand why and how self-help works and is not simply an “option” in treatment.  Int. J. Environ. Res. Public Health 2011, 8                 
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Relapse prevention (ASAM Dimension 5) can now be viewed as the processes of altered sensitivity 
and calibration of neuroadaptive circuitry, which affects hedonic tone, cue reactivity, and executive 
functioning. Warning patients that entering high risk situations during early recovery (the patient who 
frequents bars and who decides that it’s OK to play pool with his friends at the bar and drink soda), is 
not simply a matter of choice, but represents unintentional pressure upon altered circuitry. Understanding 
RDS concepts and the rate of restoration of recovery based neuroadaption allows for the patient to 
understand that the therapist recommendation is not punitive but protective. Many addicts do not 
understand that once the alcohol and drugs leave the body that the brain takes a long time to recover 
and may only reset itself to a genetically determined pre-morbid state. RDS emphasis the dynamics of 
neuroadaption of recovery and provides hope that improvement is possible, but at a rate of change that 
is dependent upon the amount of targeted treatment effort and the rate limiting steps from a biological 
perspective. 
ASAM Dimension 6 (recovery environment) emphasizes the environmental impact on treatment 
effectiveness and encompasses the interactivity of gene expression by environment factors. Patients 
tend to underestimate the power of the environment in influencing outcome and tend to justify 
maintenance of their old relationships and living situations as an independent factor. Once patients 
understand the bidirectional aspect of the recovery environment, their motivation for making difficult 
changes can be modified by these biologically based factors.  
5. Limitations, Caveats and Future Directions 
While we agree with the work of Sussman et al. [215] and his eloquent PACE model in terms of 
drug specificity based on many environmental elements, we further suggest that neurochemistry and 
certain specific genetic polymorphisms may lead to a non-specific hierarchical list of drugs of abuse 
and behaviors having a common neuro-chemical mechanism such as dopamine release in the NAc. 
However, this so called RDS phenotype is significantly impacted by availability of drugs,; awareness 
of drug availability, specific preference for one type over another type (depressant vs.  stimulant), 
among other factors.  
Additional studies are required prior to any definitive interpretation of these data. We encourage 
other investigators to extend this work by analyzing many more families for hypodopaminergic 
genotypes. This should include D1–D5 receptors, MOA-A,B, COMT, as well as other reward genes. 
Certainly studies involving larger populations even in a few families over many generations (if 
possible) would strengthen this potentially important concept. Our laboratory is continuing our pursuit 
to enhance our knowledge base by carrying out linkage analysis to couple hypodopaminergic gene 
function with RDS behaviors. We encourage other investigators to perform similar experiments.  
6. Conclusions 
While there have been other reports that help establish the RDS concept [169-171], additional 
research from multiple laboratories is warranted. The results summarized herein provide preliminary 
support for the hypothesis that dopaminergic genes, in particular the DRD2 and DAT1 polymorphisms, 
are significantly associated with the reward-dependent traits [172]. Although based on limited sample 
sizes, our findings may have direct implications for both the diagnosis and targeted treatment of RDS Int. J. Environ. Res. Public Health 2011, 8                 
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behaviors by analyzing the association of these dopaminergic genes and RDS behaviors in the form of 
proprietary algorithms or GARS. This research underscores the potential involvement of at least D2 
receptor dysfunction as an important genetic antecedent to addiction as a disease. In keeping with the 
notion of common neurogenetic mechanisms, for impulsive, compulsive and addictive disorders, we 
propose that RDS is a basic phenotype covering many reward behaviors and pertinent psychiatric 
disorders (including spectrum disorders and Posttraumatic Stress Disorder) that should be included in 
the future in DSM as a genetic umbrella for many psychiatric diagnoses.  
While we are still evaluating these results using linkage analysis (requiring a different set of 
statistics), our present results suggest a paradigm shift in thinking about selecting appropriate 
phenotypes (controls and experimental) for reward dependence behaviors (due to reward deficiency). 
Further confirmation of these results should provide an impetus for appropriate and careful selection 
and screening of controls especially in reward dependence association studies in order to reduce the 
possibility of spurious outcomes (e.g., [173,211]). 
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